News

Biovica’s DiviTum® acknowledged in ASCO educational book

Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors.

May 22, 2020

Biovica’s DiviTum® and TK activity acknowledged in highly renowned scientific journals

Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors. The editorials conclude that DiviTum data has the potential to become a standard prognostic biomarker and tool for early recognition of treatment resistance in metastatic breast cancer.

May 11, 2020

Biovica provides market share target at today’s Capital Market Day

Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica’s market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.

Reminder: Biovica invites to virtual Capital Markets Day 11 May

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00.

May 6, 2020

Biovica invites to virtual Capital Markets Day 11 May

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.

April 29, 2020

Biovica initiates a collaboration with Mayo Clinic to study DiviTum® for the on-treatment monitoring of metastatic breast cancer patients receiving CDK 4/6 inhibitors

Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum® as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.

April 8, 2020

Biovica strengthens its commercial leadership

Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone in the upcoming commercialization of DiviTum® on the US market.

March 25, 2020

Positive results from Swedish study with DiviTum in metastatic breast cancer published in prestigious journal

Uppsala, Sweden, March 12, 2020. Biovica, active in cancer diagnostics, today announced that results from a study by researchers at Lund University have been published in the well renowned journal Scientific Reports, a journal from Nature. The results support that the blood test DiviTum can be used as a prognostic tool for evaluating treatment outcomes in metastatic breast cancer.

March 12, 2020

DiviTum – first study published on CDK4/6 inhibitor against clinical results

Period: May-January 2019/2020

Biovica provides updates on FDA application

Uppsala, Sweden, March 10, 2020. Biovica, active in cancer diagnostics, today announced that the company intends to submit an FDA application for market approval of DiviTum in the third quarter of 2020 and not as previously announced in mid-2020.

March 10, 2020